Emerging Pharmacotherapy Landscape for MASLD and MASH
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Straatmijer T, Mulder M
Aug 28, 2026 · Published in: British Journal of Clinical Pharmacology
Also in Gastroenterology / Hepatology
Innovative treatments for MASLD target diverse pathways.
Incretin Therapies Reshape Post-Bariatric Weight Recurrence Management
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Huerta Díaz LA, Lopez Alanis BA, Zorrilla-Nuñez LF, et al.
Aug 28, 2026 · Published in: Cureus
Incretin-based therapies redefine post-bariatric weight management.
Anti-Obesity Drugs and Female Reproductive Dysfunction: A Mechanistic Review
Analysis Women's Health / Reproductive Hypothesis-generating Grade: Low
Varra FN, Theodosis-Nobelos P, Varra VK, et al.
Aug 27, 2026 · Published in: Medicina (Kaunas, Lithuania)
Also in Endocrinology / Diabetes / Obesity
Anti-obesity drugs show promise for enhancing reproductive health in obese women.
Pharmacotherapy Reshapes Obstructive Sleep Apnea Management Toward Endotype-Driven Care
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Zhou R, Yin G, Zhu Y, et al.
Aug 27, 2026 · Published in: Journal of Clinical Medicine
Also in Pulmonology / Respiratory
New drug options show promise for improving sleep apnea treatment beyond CPAP.
Sitagliptin Beats Pioglitazone for Stringent HbA1c Targets in Triple Therapy
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Kim TH, Hwang Y, Woo S, et al.
Aug 22, 2026 · Published in: Medicine
Sitagliptin outperforms pioglitazone in metabolic outcomes for T2DM.
DOACs Outperform Warfarin for VTE in Morbid Obesity
Analysis Anticoagulation / Hematology Confirmatory Grade: Low
Shi J, Zhang Y, Tang Y, et al.
Aug 22, 2026 · Published in: Medicine
Also in Endocrinology / Diabetes / Obesity
DOACs might outperform warfarin for VTE in morbid obesity.
Network meta-analysis ranks once-weekly GLP-1 agonists by efficacy and tolerability
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Xu Y, Ji G, Shi C, et al.
Aug 20, 2026 · Published in: Diabetes Research and Clinical Practice
Tirzepatide outshines in efficacy but watch for side effects.
Pharmacist-Led Remote Diabetes Care Linked to Better Glycemic Control
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Zhou Y, Liu X, Tang K, et al.
Aug 19, 2026 · Published in: Frontiers in Endocrinology
Also in Ambulatory Care / MTM, Clinical Practice
Remote pharmacist-led interventions improve outcomes in type 2 diabetes mellitus.
Early Combination Cardiorenal Therapy in Diabetic Kidney Disease
★ Must Read Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Lovshin JA
Aug 18, 2026 · Published in: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Also in Nephrology
Combining therapies transforms outcomes in diabetes-related kidney disease.
Deintensification Doubled But Still Lags in Overtreated Older Diabetics
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Le P, Guo N, Misra-Hebert AD, et al.
Aug 10, 2026 · Published in: JAMA Internal Medicine
Also in Geriatrics
Exploring medication changes for older adults with diabetes.
Tirzepatide Beats Dulaglutide on Cardiorenal Outcomes in Real-World HFpEF
★ Editor's Pick Analysis Cardiology Hypothesis-generating Grade: Low
Khalil I, Hossain MI, Akter MM, et al.
Aug 10, 2026 · Published in: Clinical Cardiology
Also in Endocrinology / Diabetes / Obesity
Tirzepatide outperforms dulaglutide in cardiorenal protection for HFpEF.
Perceived Competence Separates GLP-1RA Weight Management Trajectories
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
McElroy JA, Bertarelli I, Maltagliati C, et al.
Aug 10, 2026 · Published in: Obesity (Silver Spring, Md.)
Also in Ambulatory Care / MTM
Patient competence levels influence success with GLP-1 therapy for weight loss.
GLP-1 Receptor Agonists Show No Excess Bowel Obstruction Risk
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Matsuo Y, Okada A, Sakamoto T, et al.
Aug 9, 2026 · Published in: Diabetes, Obesity & Metabolism
Also in Gastroenterology / Hepatology, Medication Safety
GLP-1 receptor agonists show no increased bowel obstruction risk compared to SGLT2 inhibitors.
SGLT2 Inhibitors Show No Significant Serious UTI Excess
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Matteucci A, Di Fusco SA, Bonanni M, et al.
Aug 7, 2026 · Published in: Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences
Also in Infectious Disease / Antimicrobials
SGLT2 inhibitors show no significant rise in UTI risk.
Second-Line Agents Delay Insulin Versus Secretagogues in Type 2 Diabetes
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Yu YH, Zhang Q, Zapata-Bravo E, et al.
Aug 7, 2026 · Published in: Diabetes, Obesity & Metabolism
Second-line antidiabetic drugs play a key role in delaying insulin therapy.